We further explored the relationship between the co-expression levels of TIM-3 with TIGIT or 2B4 and clinical features as well as prognosis in NPC, hoping to provide evidence for the potential use of dual inhibition of TIM-3 and TIGIT or 2B4 as a combination treatment strategies for NPC. This evidence concerns the gene TIGIT and nasopharyngeal carcinoma.